Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04987489 · ClinicalTrials.gov registry record · Phase 2
A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease
A Phase 2 study of Sickle Cell Disease and Thalassemia, sponsored by Forma Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
- 20
- Study locations
NCT04987489: Completed Phase 2 study of Sickle Cell Disease and Thalassemia, sponsored by Forma Therapeutics.
NCT04987489 is a Phase 2 study of Sickle Cell Disease and Thalassemia that has completed, run by Forma Therapeutics. The registered enrollment target is 53 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04987489, a Phase 2 study of Sickle Cell Disease and Thalassemia, has completed, sponsored by Forma Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
- 20
- Study locations
Study Summary
This clinical trial is a Phase 2 study that will evaluate the safety and clinical activity of etavopivat in patients with thalassemia or sickle cell disease and test how well etavopivat works to lower the number of red blood cell transfusions required and increase hemoglobin.
Primary Outcome
Proportion of patients with ≥ 20% reduction in red blood cell transfusions over a continuous 12-week treatment period versus baseline red blood cell transfusion history
Conditions Studied
Interventions
- DRUG Etavopivat tablets
Study Locations (20)
California
- TOI Clinical Research - Cerritos
- [Legal] Children's Hospital Los Angeles - Los Angeles
- University of Californ LA-UCLA - Los Angeles
- UCSF Oakland Benioff ChildHosp - Oakland
- [Legal] Children's Hospital of Orange County on behalf of CHOC Children's Hospital of Orange County - Orange
- UCI Health - Orange
Ontario
- Master Centre for Canada - Mississauga
- The Hospital for Sick Children - Toronto
- University Health Network - Toronto General Hospital - Toronto
North Carolina
- Duke University - Durham
- East Carolina University - Greenville
Other
- Cairo University - Cairo
- Abu El-Reesh El-Mounira Children University Hospital - Cairo, Egypt
District of Columbia
- Children's National Health Hospital - Washington D.C.
Georgia
- Children's Hospital of Atlanta - Atlanta
Michigan
- [Legal] Dr. Vince Clinical Research, LLC and Dr. Vince Clinical Research, P.A. - Detroit
New York
- Weill Medical College of Cornell University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2022-03-28 |
| Est. Completion | 2025-09-24 |
| Phase | Phase 2 |
What the finished NCT04987489 record still lists
NCT04987489 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (82% lower).
The record links to 2 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which Etavopivat tablets is the first listed.
NCT04987489 names 20 study sites across 11 states, led by California, Ontario, North Carolina.
Frequently Asked Questions
What is clinical trial NCT04987489 about?
NCT04987489 is a clinical study titled "A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease". This clinical trial is a Phase 2 study that will evaluate the safety and clinical activity of etavopivat in patients with thalassemia or sickle cell disease and test how well etavopivat works to lower the number of red blood cell transfusions required and increase hemoglobin.
What is the current status of trial NCT04987489?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2022-03-28. Estimated completion is 2025-09-24.
What conditions does trial NCT04987489 study?
This clinical trial studies the following conditions: Sickle Cell Disease, Thalassemia.
What interventions are being tested in trial NCT04987489?
The interventions under investigation include: Etavopivat tablets (DRUG).
Who is sponsoring clinical trial NCT04987489?
This trial is sponsored by Forma Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04987489 being conducted?
This trial has 20 study locations across California, District of Columbia, Georgia, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04987489's enrollment target sits among peer trials
53 102nd of 213 higher than 110 of 213 other Sickle Cell Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET
RECRUITING · Phase 2
-
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
RECRUITING · Phase 2
-
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
RECRUITING · Phase 2
-
A Phase 2/3 Study in Adult and Adolescent Participants With SCD
RECRUITING · Phase 2
-
Allo HSCT for High Risk Hemoglobinopathies
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI